163 related articles for article (PubMed ID: 25153512)
1. Attenuation of lung cancer stem cell tumorigenesis and metastasis by cisplatin.
Wang S; Ma S; Li X; Xue Z; Zhang X; Fan W; Nie Y; Wu K; Chen X; Cao F
Exp Lung Res; 2014 Oct; 40(8):404-414. PubMed ID: 25153512
[TBL] [Abstract][Full Text] [Related]
2. Cancer stem cells and cisplatin-resistant cells isolated from non-small-lung cancer cell lines constitute related cell populations.
Lopez-Ayllon BD; Moncho-Amor V; Abarrategi A; Ibañez de Cáceres I; Castro-Carpeño J; Belda-Iniesta C; Perona R; Sastre L
Cancer Med; 2014 Oct; 3(5):1099-111. PubMed ID: 24961511
[TBL] [Abstract][Full Text] [Related]
3. NEAT1 contributes to the CSC-like traits of A549/CDDP cells via activating Wnt signaling pathway.
Jiang P; Xu H; Xu C; Chen A; Chen L; Zhou M; Haq IU; Wu X; Mariyam Z; Feng Q
Chem Biol Interact; 2018 Dec; 296():154-161. PubMed ID: 30291867
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Roles of Curcumin in Sensitising the Cisplatin Effect on a Cancer Stem Cell-Like Population Derived from Non-Small Cell Lung Cancer Cell Lines.
Abdul Satar N; Ismail MN; Yahaya BH
Molecules; 2021 Feb; 26(4):. PubMed ID: 33670440
[TBL] [Abstract][Full Text] [Related]
5. Side population cells separated from A549 lung cancer cell line possess cancer stem cell-like properties and inhibition of autophagy potentiates the cytotoxic effect of cisplatin.
Yang Y; Fan Y; Qi Y; Liu D; Wu K; Wen F; Zhao S
Oncol Rep; 2015 Aug; 34(2):929-35. PubMed ID: 26081992
[TBL] [Abstract][Full Text] [Related]
6. EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells.
Jiang P; Xu C; Chen L; Chen A; Wu X; Zhou M; Haq IU; Mariyam Z; Feng Q
Mol Carcinog; 2018 Dec; 57(12):1835-1844. PubMed ID: 30182373
[TBL] [Abstract][Full Text] [Related]
7. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
8. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
Qi MM; Ge F; Chen XJ; Tang C; Ma J
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
[TBL] [Abstract][Full Text] [Related]
9. Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma.
Hao C; Liu G; Tian G
Ther Adv Respir Dis; 2019; 13():1753466619866097. PubMed ID: 31368411
[TBL] [Abstract][Full Text] [Related]
10. Potential Role of GST-
Wang W; Wei J; Tu X; Ye X
Biomed Res Int; 2021; 2021():9142364. PubMed ID: 34840986
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of microRNA-196a enhances the sensitivity of non-small cell lung cancer cells to cisplatin treatment.
Li Q; Yang Z; Chen M; Liu Y
Int J Mol Med; 2016 Apr; 37(4):1067-74. PubMed ID: 26936095
[TBL] [Abstract][Full Text] [Related]
12. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo inhibitory effect of the combination of Wenxia Changfu formula [see text] with cisplatin in non-small cell lung cancer.
Ji XM; Ouyang B; Liu H; Liu GW; Wu ZC; Yu HY; Wang CY; Wang ZX; Wang WP
Chin J Integr Med; 2011 Dec; 17(12):908-16. PubMed ID: 22139542
[TBL] [Abstract][Full Text] [Related]
14. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
Tièche CC; Peng RW; Dorn P; Froment L; Schmid RA; Marti TM
BMC Cancer; 2016 Feb; 16():125. PubMed ID: 26895954
[TBL] [Abstract][Full Text] [Related]
15. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.
Bertolini G; Roz L; Perego P; Tortoreto M; Fontanella E; Gatti L; Pratesi G; Fabbri A; Andriani F; Tinelli S; Roz E; Caserini R; Lo Vullo S; Camerini T; Mariani L; Delia D; Calabrò E; Pastorino U; Sozzi G
Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16281-6. PubMed ID: 19805294
[TBL] [Abstract][Full Text] [Related]
16. Sulforaphane inhibits cancer stem-like cell properties and cisplatin resistance through miR-214-mediated downregulation of c-MYC in non-small cell lung cancer.
Li QQ; Xie YK; Wu Y; Li LL; Liu Y; Miao XB; Liu QZ; Yao KT; Xiao GH
Oncotarget; 2017 Feb; 8(7):12067-12080. PubMed ID: 28076844
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer.
Mattheolabakis G; Ling D; Ahmad G; Amiji M
Pharm Res; 2016 Dec; 33(12):2943-2953. PubMed ID: 27528390
[TBL] [Abstract][Full Text] [Related]
18. Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude mice.
Lee I; Kalota A; Gewirtz AM; Shogen K
Anticancer Res; 2007; 27(1A):299-307. PubMed ID: 17352247
[TBL] [Abstract][Full Text] [Related]
19. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
Huang RS; Zheng YL; Zhao J; Chun X
Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
[TBL] [Abstract][Full Text] [Related]
20. 5-O-Acetyl-Renieramycin T from Blue Sponge Xestospongia sp. Induces Lung Cancer Stem Cell Apoptosis.
Chantarawong W; Chamni S; Suwanborirux K; Saito N; Chanvorachote P
Mar Drugs; 2019 Feb; 17(2):. PubMed ID: 30754694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
